Search clinical trials for: AZD3839 Placebo

Total 53514 results

AstraZeneca

Completed

Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers

Healthy Volunteers | Alzheimer's Disease | Tolerability | Safety | Blood Concentration

United Kingdom
AstraZeneca

Terminated

A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male Subjects

Cardiovascular Disease
AstraZeneca

Completed

A Study in Participants With Non-cirrhotic NASH With Fibrosis (COSMOS)

Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

Denmark, Italy, Spain, United States, Argentina, Sweden, Mexico, Norway, Portugal
AstraZeneca
Parexel

Completed

A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease

Cardiovascular Disease

United States
AstraZeneca

Completed

AZD0837 Extended Release (ER) Japan Study (ER J ph I)

Healthy

Japan
AstraZeneca

Terminated

Safety and Tolerability Study of AZD4831 in Patients With Heart Failure. (SATELLITE)

Heart Failure

Denmark, Finland, Netherlands, United States, Sweden
AstraZeneca

Completed

Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40% (ENDEAVOR)

Heart Failure With Preserved Ejection Fraction

United States, France, Netherlands, Belgium, Taiwan, Slovakia, Japan, Czechia, Hungary, Australia, Bulgaria, Poland, Russian Federation, Brazil, Denmark, Turkey, Sweden, Canada
AstraZeneca
Parexel

Completed

A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers

Heart Failure With Preserved Ejection Fraction (HFpEF)

United States
AstraZeneca

Recruiting

An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD. (CRESCENDO)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Canada, Denmark, Germany, South Africa, Spain, United Kingdom, Italy, Argentina, Bulgaria, Mexico, Turkey, Poland, Netherlands
AstraZeneca
Eli Lilly and Company

Terminated

A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia (DAYBREAK-ALZ)

Alzheimer's Disease

United States, Spain, Korea, Republic of, Italy, Portugal, China, Taiwan, Czechia, Japan, Poland, France, Netherlands, United Kingdom, Germany, Russian Federation, Canada, Mexico, Denmark
Mayo Clinic
National Center for Advancing Translational Sciences (NCATS)

Completed

MPO Inhibitor A_Zeneca for HFpEF

Heart Failure

United States
AstraZeneca
Eli Lilly and Company

Terminated

An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease (AMARANTH)

Alzheimer´s Disease

United States, Spain, Belgium, Australia, Hungary, Korea, Republic of, Canada, Germany, Japan, Romania, France, Poland, United Kingdom, Puerto Rico, Italy
AstraZeneca

Recruiting

A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants

Healthy Participants

United States
AstraZeneca

Completed

A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers

Healthy Japanese Young and Elderly Male and Non-fertile Female Volunteers

Japan
AstraZeneca

Completed

A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients

Healthy Elderly Volunteers | Mild-to-moderate Alzheimer's Disease Patients

United States
AstraZeneca

Completed

A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects

Healthy Elderly Volunteers | Healthy Young Volunteers

United States
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Administration of AZD8329 (AZ8329)

Healthy | Overweight | Male

United Kingdom
AstraZeneca

Completed

A First Time in Man, Study to Assess the Safety of AZD8329 After Single Ascending Oral Doses

Healthy Men

Sweden
AstraZeneca
Quotient Sciences

Completed

A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833

Healthy Volunteers

United Kingdom
AstraZeneca
Parexel

Completed

A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers

Renal Impairment

Bulgaria
AstraZeneca

Completed

A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293 (AZD3293hADME)

Healthy Volunteers | Mass Balance Study

United States
AstraZeneca

Completed

Single Centre, Double-blind, Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects

Healthy Volunteers | Tolerability | Safety

United Kingdom
LYZZ Alpha Holding Ltd
Tigermed Consulting Co., Ltd

Completed

Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759

Non Small Cell Lung Cancer

China
AstraZeneca
Parexel

Completed

A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.

Healthy Volunteers

United States
AstraZeneca

Completed

Pharmacokinetics of Extended-Release Test- and Reference Formulations of AZD0837

Healthy

Sweden
AstraZeneca

Recruiting

Study of AZD9829 in CD123+ Hematological Malignancies

Hematological Malignancies

United States, Spain, Korea, Republic of, Italy, Japan, Taiwan, Australia, Germany, China
AstraZeneca

Active, not recruiting

A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer

ER+ HER2- Advanced Breast Cancer

Japan
AstraZeneca

Completed

Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

Hepatic Impairment

United States, Bulgaria, Slovakia
AstraZeneca
Quotient Sciences

Completed

A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831

Cardiovascular Disease

United Kingdom
AstraZeneca
Eli Lilly and Company

Completed

A Study of Lanabecestat (LY3314814) in Healthy Participants

Healthy
AstraZeneca
Eli Lilly and Company

Terminated

A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia

Alzheimer's Disease

United States, Spain, Australia, Belgium, Korea, Republic of, United Kingdom, Germany, Poland, Canada, Japan, Romania, France, Puerto Rico, Hungary
AstraZeneca

Completed

AZD8330 First Time in Man in Patients With Advanced Malignancies

Cancer

United States, Norway
AstraZeneca

Completed

Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects (BA)

Healthy Volunteers | Pharmacologic Action

United States
AstraZeneca

Active, not recruiting

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (SERENA-1)

ER+ HER2- Advanced Breast Cancer

United States, Spain, United Kingdom
AstraZeneca

Completed

A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer (SERENA-3)

HER2-negative Breast Cancer

Mexico, United Kingdom, Georgia
AstraZeneca

Completed

Evaluation of the Pharmacokinetics and the Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 in Patients With Asthma

Asthma

Sweden
AstraZeneca

Recruiting

Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment

Hepatic Impairment

United States
AstraZeneca

Completed

A Methodology Study in Healthy Subjects to Evaluate the Effect of AZD8309 After Nasal Administration of Lipopolysaccharide (LPS)

Healthy

Sweden
AstraZeneca

Completed

A Study Conducted Over 3 Periods to Look at the Drug in the Body

Type 2 Diabetes Mellitus

United Kingdom
AstraZeneca

Completed

Excretion of Radiolabelled AZD0837

Healthy

Sweden
AstraZeneca

Completed

AZD9833 China PK Study (AZD9833)

ER+, HER2-, Metastatic Breast Cancer

China
AstraZeneca

Recruiting

A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19 (ARTEMIS-C)

COVID-19 | SARS-CoV-2 Infection

United States
AstraZeneca
Eli Lilly and Company

Completed

A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants

Healthy

United States
Genzyme, a Sanofi Company

Completed

This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

Carcinoma, Non-Small-Cell Lung

United States, South Africa, United Kingdom, Germany, Argentina, Belgium
AstraZeneca

Recruiting

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (SERENA-6)

ER-Positive HER2-Negative Breast Cancer

United States, Israel, Spain, Korea, Republic of, Italy, Poland, Belgium, Norway, Bulgaria, France, Germany, United Kingdom, Japan, Taiwan, Canada, Hungary, Australia, Austria, Portugal, Turkey, Russian Federation, Slovakia, Switzer...
AstraZeneca
Quotient Sciences

Completed

A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833

ER-positive, HER2-negative Breast Cancer

United Kingdom
AstraZeneca

Active, not recruiting

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (SERENA-4)

ER-Positive HER2-Negative Breast Cancer

Austria, Belgium, France, Germany, Italy, United Kingdom, United States, Canada, India, Taiwan, Russian Federation, Korea, Republic of, Hungary, Japan, Mexico, Turkey, China, Malaysia, Spain, Czechia, Portugal, Poland, Norway, Bulgaria, Slovaki... and more
AstraZeneca

Completed

IRESSA™ (Gefitinib) in Breast Cancer Patients

Breast Cancer
AstraZeneca

Completed

Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours

Advanced Solid Malignancies | Breast Cancer - ER+, HER2 - | Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation

United States, United Kingdom
AstraZeneca

Completed

Long-term Safety in Atrial Fibrillation Patients

Persistent or Permanent Nonvalvular Atrial Fibrillation

Search clinical trials for: AZD3839 Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations